Active	Status	Sponsor type	Region	Phase	Filter
1 Active 0 Inactive 1 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes: « April » « 2025 » M T W T F S S 31 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 1 2 3 4   - « April » « 2025 » M T W T F S S 31 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 1 2 3 4   Show only changed items Enrollment:

Advanced Filters

1 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Udani, Vrajesh
REBUILD-2, NCT04616326 / 2018-004622-28: A Study of Galcanezumab (LY2951742) in Participants 12 to 17 Years of Age With Chronic Migraine	Recruiting	3	300	Europe, Japan, US, RoW	Galcanezumab, LY2951742, Placebo	Eli Lilly and Company	Chronic Migraine	07/25	03/26
Vrajesh, Udani
No trials found
Thakre, Sandip
No trials found
Kelaskar, Snehal
No trials found
Colaco, Philadelphia
No trials found

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Udani, Vrajesh
REBUILD-2, NCT04616326 / 2018-004622-28: A Study of Galcanezumab (LY2951742) in Participants 12 to 17 Years of Age With Chronic Migraine	Recruiting	3	300	Europe, Japan, US, RoW	Galcanezumab, LY2951742, Placebo	Eli Lilly and Company	Chronic Migraine	07/25	03/26
Vrajesh, Udani
No trials found
Thakre, Sandip
No trials found
Kelaskar, Snehal
No trials found
Colaco, Philadelphia
No trials found